Related references
Note: Only part of the references are listed.An Oracle: Antituberculosis Pharmacokinetics-Pharmacodynamics, Clinical Correlation, and Clinical Trial Simulations To Predict the Future
Jotam Pasipanodya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Moxifloxacin Pharmacokinetics/Pharmacodynamics and Optimal Dose and Susceptibility Breakpoint Identification for Treatment of Disseminated Mycobacterium avium Infection
Devyani Deshpande et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium avium
Devyani Deshpande et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Dosing Ethambutol in Obese Patients
Devyani Deshpande et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation
John Koreth et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Efflux-Pump-Derived Multiple Drug Resistance to Ethambutol Monotherapy in Mycobacterium tuberculosis and the Pharmacokinetics and Pharmacodynamics of Ethambutol
Shashikant Srivastava et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis
Charles A. Peloquin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Isoniazid bactericidal activity and resistance emergence: Integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases
David E. Griffith et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis:: Evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy
Radha K. Shandil et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth
Tawanda Gumbo et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore
Paul G. Ambrose et al.
CLINICAL INFECTIOUS DISEASES (2007)
Therapy of nontuberculous mycobacterial disease
David E. Griffith
CURRENT OPINION IN INFECTIOUS DISEASES (2007)
Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages
M Barcia-Macay et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare among patients without AIDS
XY Han et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2005)
Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance
T Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Elemental analysis of Mycobacterium avium-, Mycobacterium tuberculosis-, and Mycobacterium smegmatis-containing phagosomes indicates pathogen-induced microenvironments within the host cell's endosomal system
D Wagner et al.
JOURNAL OF IMMUNOLOGY (2005)
Relationship between fluoroquinolone area under the curve:minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia
GL Drusano et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'
GL Drusano
NATURE REVIEWS MICROBIOLOGY (2004)
Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy
PC Karakousis et al.
LANCET INFECTIOUS DISEASES (2004)
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling
T Gumbo et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome
CA Benson et al.
CLINICAL INFECTIOUS DISEASES (2003)
Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with bronchopneumonia
N Simon et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Discrepancy between uptake and intracellular activity of moxifloxacin in a Staphylococcus aureus-human THP-1 monocytic cell model
D Paillard et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations
JE Conte et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Symptomatic and health status outcomes in the Canadian randomized MAC treatment trial (CTN010)
J Singer et al.
INTERNATIONAL JOURNAL OF STD & AIDS (2000)
Share Paper
